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p53 proteins expressed in vivo
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Summary p53 is activated in response to DNA damage and functions in the maintenance of genetic integrity. Loss of p53 function because
of mutation of the p53 gene is associated with over half all human cancers. Certain human p53 mutants are conformationally flexible in vitro
and are temperature sensitive, with partial or complete recovery of wild-type (wt) properties at 320C. We have now tested the functional
capacities of selected p53 mutants in vivo, by transfection into established human cell lines. Unexpectedly, we found that wt p53 can be
temperature sensitive for transactivation of a co-transfected target gene in vivo. Flexible mutants retained varying degrees of functional
capacity in tranfected cells, and the recipient cell line appeared to be a significant determinant of both wt and mutant p53 function; importantly,
two p53 null cell lines commonly used to study p53 function (Saos-2 and Hep3B) differed markedly in this latter respect. We also show that
the p53 mutant V272M, which exhibits sequence-specific DNA binding in vitro, is nonetheless defective for transactivation and is unable to
induce apoptosis in vivo. The valine 272 residue may thus be crucial for properties (other than sequence-specific DNA binding) that are
important for p53 function(s) in vivo.
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The importance of the tumour-suppressor p53 in human cancer is
well documented (for recent reviews please see Hainaut, 1995a;
Milner, 1995; Ko and Prives, 1996). The p53 protein functions to
activate the cellular response to DNA damage, thereby helping in
the maintenance of genetic integrity and normal cell growth
control. The conformational structure of the p53 protein is flex-
ible, and this appears to be important for function (see Milner 1995
and references therein). Missense point mutations can destabilize
the 'wild-type' (wt) p53 conformation that is necessary for trans-
activation of p53 target genes and for the induction of G1 arrest.
p53 can also induce apoptosis (reviewed in Canman and Kastan,
1995), and recent evidence suggests that certain mutants of p53
that are unable to transactivate target genes nonetheless retain the
ability to induce apoptosis (Haupt and Oren, 1996).
Some mutants of p53 are temperature sensitive. The first func-
tionally temperature-sensitive mutant was discovered by Oren and
colleagues (Michalovitch et al, 1990). This mutant, murine p53
V135A, was found to be functionally inactive at 37.5°C but func-
tioned to suppress cell proliferation at 32.5°C. Subsequent studies
showed that V135A is structurally flexible and temperature sensi-
tive for conformation when expressed in vitro (Milner and
Medcalf, 1990), with wt and 'mutant' conformations correlating
with the observed functional properties in cells. A mutant of
human p53, hp53 V143A, is also temperature sensitive for func-
tion. At 37°C this mutant is transcriptionally inactive but, at 32°C,
it transactivates several p53 responsive promoters. Nonetheless,
hp53 V143A is deficient for the complete repertoir ofp53 functions
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as it is unable to induce apoptosis at 37°C (Friedlander et al,
1996a). This suggests that the effects oftemperature on p53 struc-
ture and function are subtle and may be differentially affected by
different missense point mutations of the protein.
In vitro screening ofp53 has now been usedto identify human p53
mutants, known to occur in human cancers, that are also temperature
sensitive for conformational structure (Medcalfet al, 1992; Rolley et
al, 1995). In the present study, we have selected examples of such
mutants and assessed their functional properties in vivo.
Our original aim was to obtain stable transfected cell lines for
each mutant p53. However, as p53 is able to induce cell growth
arrest and/or apoptosis it is difficult to obtain cells that tolerate
stably transfected p53 with wt properties. An alternative approach
to the problem is to use transient transfection assays and this
approach has been widely used to study the functions ofwt p53 and
p53 mutants. Cell lines commonly used for such studies include
Saos-2 and Hep3B as they are p53 null and experimental observa-
tions are therefore uncomplicated by the presence of endogenous
p53 (see for example Ponchel et al, 1994; Forrester et al, 1995;
Yamato et al, 1995; Jiang et al, 1996; Friedman et al, 1997). Other
lines such as HepG2 and MCF-7 express endogenous wt p53 and
are used to study the p53 response to DNA damage, to different
drugs and to different types of stress (Guillot et al, 1996; Muller et
al, 1997; Ogretman and Sula, 1997 and references therein).
In the present study we have used these four human cell lines
(Table 1) to study the functional capacity of human wild-type and
mutant p53 proteins in transient transfection assays. Two flexible
and one inflexible p53 mutant (Table 2) were selected for detailed
functional analyses at 32°C and at 37°C. Unexpectedly, we found
that temperature had a marked effect on the transcriptional activity
of wt p53. The flexible mutants were also temperature sensitive,
albeit to different degrees, whereas the inflexible mutant (M2371)
was non-functional under all conditions tested.
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Table 1 Cell lines description
Cell line Origina Passages p53 Rb Number of Response to
used chromosomes wt p53 over
per cell expression
HEP3B ETCC (90) p90-110 Null Null 60 Apoptosis
SAOS-2 ATCC (29) p35-45 Null Null 56 G, arrestand apoptosis
HEPG2 ATCC (75) p80-95 wt wt 55 G, arrest
MCF7 ATCC (138) Unknown wt ? 82 G, arrest
aETCC, European tissue collection; ATCC, American tissues collection. Initial passage number when received is shown in brackets
Table 2 p53 mutants description (Rolley et al, 1995)
p53 protein Conformationa DNA bindingb
370C 300C 300C
p53
WT WT WT ++
p53-M237R MT WT +++
p53-M2371 MT MT
p53-V272M MT WT ++
aConformation determined using in vitro translation and immunoprecipitation.
bDNA binding determined using in vitro translation and EMSA with pCON
oligonucleotide. WT, wild type conformation; MT, mutant conformation.
MATERIALS AND METHODS
Cell culture
The cells lines used are listed in Table 1. Hep3B (Aden et al, 1979;
passage number 90-110), HEPG2 (Aden et al, 1979), Saos-2
(Fogh andTrempe, 1975) and MCF-7 (Soule, 1973) cell lines were
grown in Dulbecco's modified Eagle medium (DMEM) containing
10% fetal calf serum, 2 mM L-glutamine, 200 units ml-1 penicillin,
and 200 jig ml-' streptomycin, at 37°C or 32°C in a humidified 5%
carbon dioxide incubator. Cells to be grown at 32°C were routinely
preincubated at 37°C for 6 h to facilitate adherence to the culture
plastic before shifting to 32°C.
FACS analysis
Cells were trypsinized, washed and fixed in 70% methanol in
phosphate-buffered saline (PBS) for 15 min, -20°C. Cells were
washed twice with PBS and further incubated in the presence of
RNAase A (0.5 jig ml-1) for 1 h at 37°C. After addition of
propidium iodine (50 jig ml-'), cell cycle analysis was performed
using FACSort flow cytometry (Becton Dickinson). A total of
20 000 cells were counted to determine cell cycle profiles.
Plasmids
cDNAs encoding wt and mutant p53s (Rolley et al, 1995) were
cloned under control of a CMV promoter into the pRC/CMV
mammalian expression vector (Invitrogen), which contains a
neomycin resistance selective marker. pRGC-Afos-lacZ was used
as reporter plasmid (Frebourg et al, 1992). It contains two binding
sites derived from the RGC (ribosomal gene cluster) p53-respon-
sive element and has the advantage of using genomic sequences
instead of artificial consensus repeats (Frebourg et al, 1992). The
two p53-binding sites were constructed in tandem, proximal to a
minimal c-fos promoter (TATA box) and a lacZ reporter gene.
pCAT-control plasmid (Promega) was used to assay transfection
efficiency.
Transient transfection
Transfections were performed using lipofectamine (Gibco BRL).
Cells were seeded into 12-well plates 24 h before transfection in
order to obtain 70%. confluence. Transfection was performed
according to the manufacturer's recommendations. An aliquot
(5 ,ul) of lipofectamine was used per transfection with 0.375 ,ug
of pRGC-Afos-lacZ DNA, 0.375 jig of p53 expression vector
DNA and 0.25 gg ofcontrol plasmid DNA.
CAT ELISA and P-galactosidase assay
After transfection with the appropriate vectors, cells were scraped
and washed in PBS. CAT activity was quantified using a CAT
ELISA kit (Boehringer Mannheim). Briefly, cell extracts were
applied on microtitre plates coated with anti-CAT antibody. A
digoxigenin-conjugated anti-CAT antibody was added as tracer.
Peroxidase-conjugated anti-digoxigenin antibody and ABST
substrate were used to quantify the amount ofCATprotein. Forthe
P-galactosidase assay cell extracts were incubated at 37°C in the
presence of a reaction mix containing 402 jil of 0.1 M sodium
phosphate pH 7.5; 132 gl of ONPG (4 mg ml-1 in sodium phos-
phate 0.1 M pH 7.5) and 6 jl of 0.1 M magnesium chloride, 4.5 M
3-mercaptoethanol (Maniatis et al, 1987). The reaction was
stopped by adding 1 ml of 1 M sodium carbonate solution. Optical
densities were read at 420 nm.
Immunostaining
Cells were grown on coverslips and transfected with the appro-
priate plasmids. PAb240, PAb1801 and PAb421 monoclonal anti-
bodies were used as a cocktail to detect p53. Cells were washed,
fixed in paraformaldehyde (3% in PBS) for 15 min, preincubated
with bovine serum albumin (BSA) (3% in PBS) for 30 min and
further incubated for 1 h in the presence of primary antibody at
room temperature. Secondary FITC-conjugated antibody (rabbit
anti-mouse immunoglobulin; Dako), was added for 45 min and
p53 visualized by indirect immunofluorescence.
Detection of apoptosis
Cells stained for p53 were washed in PBS and stained with
propidium iodine (Sigma 50 jig ml-1 in PBS) for 5 min, washed
twice in water, and observed under fluorescent light. Apoptosis
was detected as morphological alterations of nuclear staining,
counting a minimum of 150 cells.
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Figure 1 Transactivation activity of wild-type p53 in different cell lines.
Different cell lines were co-transfected with wt p53 expression vectors
(0.375 ,ug), RGC-lacZ reporter plasmid (0.375 .g9) and p-CAT-control
plasmid (0.250 ig). Galactosidase activity was measured and normalized to
CAT activity 60 h post-transfection. Activities are compared with wt p53 at
370C (taken as 100%) and represent the average of four independent
transfections. C, 37°C; U, 320C
RESULTS
Effects of temperature on wild-type p53
Comparison of the transcriptional activity of wt p53 in cells
cultured at 370C and at 32°C revealed a striking temperature-
dependent effect. The Hep3B, HepG2 and MCF-7 cell lines all
exhibited enhanced transactivation of the reporter construct when
incubated at 320C (Figure 1). This effect did not appear to reflect
an effect of temperature on cell growth as the transactivation
assays were performed at 60 h post-transfection and at this time
cell growth rates were equivalent at 370C and at 32°C (see Figure
2A for examples). Indeed, cell growth curves were essentially
identical at both temperatures for Saos-2, HepG2 (Figure 2A) and
MCF-7 cells (results not shown); for Hep3B the establishment of
growth after subculture was slower at 320C but, after 24 h, the rate
of proliferation recovered and paralleled that of cells grown at
370C (Figure 2A). The effects of temperature on cell cycle were
also checked (Figure 2B: results shown are for Hep3B, other cell
lines gave essentially similar results). Again, there was no obvious
cell cycle effect that might account for the enhanced transcrip-
tional activity ofwt p53 at 32°C relative to 37°C.
One possible explanation for the observed effect of temperature
on the transcriptional activity ofp53 lies in the effect oftemperature
on the dissociation ofp53-DNA complexes. It has been noted that
the dissociation of wt p53 from a sequence-specific DNA target
was markedly increased when the complexes were incubated in
vitro at 300C as opposed to 20°C (Hall and Milner, 1995; AJ Hall
and J Milner, unpublished observations). If p53-DNA complexes
are similarly stabilized at lower temperatures in cells, this might
contribute to the enhanced transactivation effect observed at 32°C
as opposed to 37°C (Figure 1). However, other factors must also be
involved as the Saos-2 cells showed equivalent levels oftransacti-
vation by p53 at both 37°C and at 32°C (Figure 1). This suggests
that cellular factors that are intrinsic to individual cell lines can
also influence the efficacy of transactivation by wt p53 in a tran-
sient transfection assay. Such factors may be linked with cell type
and/orthe number ofpassages in culture as the Saos-2 cells used in
this study had been passaged between 35-45 times, whereas the
Hep3B line had been passaged 90-110 times (see Table 1). Indeed
progressive loss of genetic integrity is predicted for p53-null cell
lines such as Saos-2 and Hep3B.
The observed difference in the effect of temperature on trans-
activation by wt p53 indicates a fundamental difference between
the Hep3B and Saos-2 cell lines. As both cell lines are frequently
used to study the functions ofp53, this observation is an important
consideration when assessing and comparing results from different
research groups.
Effects of temperature on p53 mutants
We next tested the ability of selected p53 mutants to transactivate
the RGC reporter gene at 30°C and at 37°C. All four cell lines
(listed in Table 1) were used. The characteristics ofthe p53 mutant
proteins after expression in vitro are listed in Table 2. In all cases
the inflexible mutant, M2371, failed to show any transactivation
activity (Figure 3). The two flexible mutants differed markedly in
their transactivation potential after transfection into cells (Figure
3), even though they both exhibit equivalent sequence-specific
DNA-binding properties in vitro (Rolley et al, 1995). Thus,
M237R was similar to wt p53 in all four cell lines at 37°C. This
similarity was also observed at 32°C in each cell line with the
exception of HepG2, which did not exhibit a temperature-
dependent effect with M237R (Figure 3).
In contrast, the second flexible mutant, V272M showed little or
no transactivation at 37°C in any of the cell lines tested. In cells
incubated at 32°C, V272M showed some transactivation of the
RGC reporter in the two p53 null cell lines and in HepG2 cells.
In vitro studies have shown that V272M exhibits equivalent
sequence-specific DNA binding to the wtp53 protein (Rolley et al,
1995). Our present observation that V272M is deficient for trans-
activation in vivo suggests that valine at residue 272 plays a role in
other molecular interactions that are important for p53 function.
Ability of mutant p53 proteins to induce apoptosis
It has recently been reported that some mutants of p53 retain the
ability to induce apoptosis, even though they have lost DNA-
binding capacity and are unable to transactivate p53 target genes
(Haupt and Oren, 1996). We therefore next assessed apoptosis
after transient transfection with wt p53 and with p53 mutants.
Hep3B cells were selected for this study as they undergo apoptosis
in preference to G, arrest in response to overexpression of wt p53
(see Table 1).
As expected, wt p53 induced apoptosis in the Hep3B cells,
whereas the inflexible M2371 mutant failed to induce any response
(Figure 4A). Interestingly, with wt p53 there was no enhanced
effect at 32°C compared with 37°C. This is in contrast to the
striking enhancement oftransactivation activity of wt p53 at 32°C
in Hep3B cells (Figure 1). The flexible mutant M237R also
induced apoptosis, albeit to a lesser extent than the wt protein
(Figure 4A). However, the flexible V272M mutant was inefficient
at inducing apoptosis, with only 10% of those cells expressing
high levels ofp53 protein showing apoptotic nuclei (see Figure 4B
for morphological characteristics).
DISCUSSION
Use of transient transfection for the study of p53 protein function
has proved informative for those investigations that do not require
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Figure 2 (A) Growth curves of HEP3B, SAOS-2 and HEPG2 cells at 370C and 320C. Cells were seeded into 12-well tissue culture plates at 370C, incubated
overnight, then at either 370C or 320C (time zero). Cell viability (103 cells per well) was estimated by trypan blue exclusion every 24 h. Open symbols represent
cells at 370C and closed symbols cells at 320C. (B) Cell cycle analysis of HEP3B cells grown at 370C and 320C. Cells were seeded into 6-well tissue culture
plates at 370C overnight then at either 370C or 320C. Cell cycle analyses were performed at equivalent confluences using flowcytometry. G,, S and GJM fraction
were 65%, 11%, 24% and 60%, 13%, 27% at 370C and 320C respectively
ongoing proliferation of the transfected cells (see for example the
recent papers by Haupt et al, 1997, and Kubbutat et al, 1997).
Established cells lines that are null for p53 are usually selected for
such studies, including the human Saos-2 osteosarcoma line and
Hep3B hepatocellular carcinoma cell line. Our results now
demonstrate a significant difference between the functional
capacity of wt p53 after transfection into Saos-2 compared with
Hep3B cells. This difference is manifest by the enhanced transac-
tivation of the RGC reporter plasmid at 32°C in Hep3B cells. The
results shown are for cells assayed 60 h after transfection and
represent the means offour experiments (Figure 1). Similar results
were obtained 48 h after transfection (again taking the mean of
four experiments, data not shown). The effects of temperature on
p53 transactivation activity could not be explained by altered cell
growth rate or by altered cell cycle at 32°C, and may reflect stabi-
lization of p53-DNA complexes in conjunction with biochemical
properties specific to the individual cell lines (see Results). Other
factors known to impinge upon p53 in a temperature-dependent
manner include heat shock protein 70 (hsp70; Hainaut and Milner,
1992 and references therein) redox and metal chelation (Hainaut
and Milner 1993a,b; Verhaegh et al, 1997). Any or all these factors
may contribute towards the enhanced properties of p53 in Hep3B
cells cultured at 32°C. The HepG2 and MCF-7 cell lines also
showed enhanced transactivation of the RGC reporter plasmid at
32°C after transfection with wt p53 (Figure 1). In these two cell
lines transactivation by the endogenous wt p53 was either not
detectable (HepG2) ordid not appear to be affectedby temperature
(MCF-7; see Figure 3, controls).
In human cancer the methionine residue at position 237 of p53
can be substituted by missense point mutation to either arginine
(M237R) or isoleucine (M2371). These alternative substitutions at
residue 237 have strikingly different consequences at the level of
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Figure 3 Transactivation activity of flexible mutants in different cell lines. Different cell lines were co-transfected with wt or mutant p53 expression vectors
(0.375 tg), RGC-IacZ reporter plasmid (0.375 ,g) and p-CAT-control plasmid (0.250gg). Four independent transfections were performed. Galactosidase
activity was measured and normalized to CAT activity 60 h post-transfection. Activities are compared with wt p53 transactivation as for Figure 1. Activity at 370C
and 320C are represented by open bars and solid closed respectively. Control, reporter plus CMV vector
protein structure. Thus, substitution to isoleucine at residue 237
completely abrogates the ability of the mutant protein to adopt the
wt conformation and results in complete loss of ability either to
transactivate a target gene or to induce apoptosis (Figures 3 and 4).
In contrast, M237R retains the ability to adopt the wt p53 confor-
mation and can bind a sequence-specific DNA target when trans-
lated in vitro at 30°C, whereas at 37°C it adopts the mutant
conformation and fails to show sequence-specific DNA binding
(Rolley et al, 1995). Our present results show that this structurally
temperature-sensitive mutant is also temperature sensitive for
function when transfected into Hep3B cells. Indeed, it behaves
very much like the wt p53 in transient transfection studies, with wt
properties at both 32°C and at 37°C (Figure 3). The ability of
M237R to transactivate a target gene at 37°C indicates that cells
are able to drive the conformational folding of this protein into
the wt form required for sequence-specific DNA recognition and
binding.
Methionine 237 is located on loop 3 of the molecular structure
of the p53 core domain (Cho et al, 1994) and is close to the zinc
atom that helps stabilize the tertiary conformation of wt p53.
Substitution to arginine may allow similar spatial organization to
the wt protein under permissive conditions. This could account for
the wt-like functions ofthe flexible M237R mutant. Substitution to
isoleucine at residue 237 is likely to disrupt this crucially impor-
tant domain because of the bulky nature of isoleucine and lack of
steric flexibility. This would account for the inability ofM2371 to
adopt the wt conformation and its complete lack of functional
activity.
Substitution ofvaline 272 with methionine (V272M) results in a
p53 mutant protein that is largely indistinguishable from M237R
when expressed in vitro. Both V272M and M237R are temperature
sensitive for conformation and bind a sequence-specific DNA
target when translated at 30°C (Rolley et al, 1995). However, we
now show that the ability ofV272M to transactivate a p53-specific
target gene or to induce apoptosis of transfected cells is greatly
impaired, whereas M237R appears similar to wt p53.
Loss of function associated with the V272M mutant is more
difficult to rationalize from the molecular structure ofp53. Valine
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Figure 4 (A) Induction of apoptosis in HEP3B cells expressing wt or mutant p53. O, 37°C; E 320C. (B) Morphological assessment of apoptosis. Hep3B cells
were transfected with wt or mutant p53 expression vectors (1 gg DNA). p53 protein expression was detected by indirect immunofluorescence and DNA staining
with propidium iodine 72 h after transfection using confocal microscopy. Apoptosis was scored in p53-positive cells presenting morphological features of
chromatin condensation, as shown for p53-M237R (a, arrow) compared with non-apoptotic cells expressing p53-M2371 (b, arrow). Scale bars = 10gm
272 lies on 1-strand 10 within the p53 core domain (Cho et al,
1994) and is at the edge of two hydrophobic clusters. Substitution
of methionine for valine at this site is unlikely to have any severe
effect on conformational folding, and this is borne out by the
ability of the V272M mutant to adopt the wt phenotype with
sequence-specific DNA binding when expressed at 30°C in vitro
(Rolley et al, 1995). Nonetheless, V272M is clearly grossly
impaired fornormal functioning in the cell (Results), implying that
V272 may be important for intramolecular interactions involved in
p53 transactivation and induction ofapoptosis.
Our results indicate that the functional properties of wt p53 can
vary with temperature and with cell line when the protein is over-
expressed after transient transfection. In particular, Saos-2 and
Hep3B differ markedly and it is possible that these two p53-null
cell lines may have diverged because ofgenomic instability in the
absence of p53. It is equally possible that established p53-null
lines derived from Saos-2, for example, may also differ between
different laboratories depending on passage number. Indeed, in the
case of Hep3B we have evidence that the functioning of certain
p53 mutants vary according to cell passage number(FPonchel and
J Milner, unpublished observations). It follows that use ofp53-null
cells to study the functional properties of p53 should ideally be
restricted to primary cells and cell lines with low passage number.
In summary, we believe that our results have important implica-
tions for experimental model systems currently used to study the
functions of wild-type and mutant p53 proteins. In particular, we
emphasize the observed variation between different p53-null cell
lines, that may, in part, reflect the inherent genetic instability of
such cell lines.
It is hoped that information gained from the study ofp53 in cell
culture will, in the longer term, prove useful for the development
of novel therapies for the treatment of cancer. The first message
from our present study is that it is not sufficient to simply classify
p53 in tumour cells as either wild type or mutant. Not all mutants
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cause complete loss of p53 function and there is a realistic possi-
bility of rescuing wt function for many clinically relevant p53
mutants. In our own studies we have screened for mutants able to
function at lowered temperatures. However, we are unable to
discuss our observations in relation to current clinical therapies as
there is little published information on the use of hypothermia in
cancer therapy. Hyperthermia, on the other hand, has been used in
conjunction with radiotherapy for the treatment of certain tumour
types. Based on observations on the behaviour of both wt and
mutant p53 proteins at different temperatures (Hainaut et al,
1995b, Rolley et al, 1995; Friedlander et al, 1996b; Hansen et al,
1996; this paper) we would predict minimal involvement of p53
under hyperthermic conditions. This would be consistent with the
observed lack ofcorrelation between p53 genetic status and effects
of preoperative radiochemohyperthermia therapy for rectal cancer
(Ichikawa et al, 1996).
There is evidence that cellular factors can influence restoration
ofwt functions to certain p53 mutants (see above) and future work
aims to identify these factors. Such information should lead to
informed screening for potential therapeutic agents that may simi-
larly enhance the functional capacity of mutant p53 proteins. It
should also be remembered that the ability of p53 to transactivate
target gene expression is not essential for its ability to induce
apoptosis (Haupt et al, 1995). Thus, for some mutants, it may be
possible to activate p53-dependent apoptotic pathways (even
though their transactivation potential has been irrevocably lost)
and so induce selective killing ofthe affected tumour cells.
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